| P/E (FY) | — | Sales (TTM) | $114.9M |
| Earnings (TTM) | -$107.8M | ROE | −5.98% |
| Net Margin | −8.78% | ROIC | −196.41% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 175.88% |
| Market Cap | $369.7M | Trading Days | 943 |
| 52W High | 3.04 |
| 52W Low | 0.43 |
| % Off High | −32.57% |
| YTD | 106.03% | 1Y | 220.31% |
| 3Y | −31.89% | Since incept. (ann.) | −34.03% |
Single Reportable 100%
| Ann. Volatility (1Y) | 97.31% | Ann. Volatility (3Y) | 89.82% |
| Sharpe (1Y) | 1.67 | Sharpe (3Y) | 0.28 |
| Max Drawdown (1Y) | −36.98% | Max Drawdown (3Y) | −92.68% |
| Beta (3Y, vs SPY) | 2.68 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc | $370.7M | — |
| CMPX | Compass Therapeutics, Inc. | $367.4M | — |
| AUTL | Autolus Therapeutics plc | $385.9M | — |
| PALI | PALISADE BIO, INC. | $350.6M | — |
| CCCC | C4 Therapeutics, Inc. | $392.5M | — |
| STRO | SUTRO BIOPHARMA, INC. | $393.2M | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $345.3M | — |
| LXEO | Lexeo Therapeutics, Inc. | $344.7M | — |
| OCGN | Ocugen, Inc. | $419.8M | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $427.0M | — |
| NMRA | Neumora Therapeutics, Inc. |
| $307.6M |
| — |
| CABA | Cabaletta Bio, Inc. | $445.1M | — |
